{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:07:35Z","timestamp":1790352455149,"version":"4.1.0"},"reference-count":40,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Treatments for multiple myeloma (MM) have expanded in the last decade, and the overall survival (OS) of MM patients (pts) is in continuous improvement. With the availability of new treatments and the use of high-dose chemotherapy, followed by autologous hematopoietic stem cell transplantation (ASCT), the median OS of newly diagnosed MM (NDMM) pts is 6\u20138 years. To date, approximately 50% and 28% of MM patients are still alive at 5 years and 10 years. Few data are reported concerning the characteristics of the long-term survival MM pts. Methods: the aim of this observational multicenter study is to analyze the clinical profile of MM pts who have survived 10 years or longer, to identify possible predictors of long-term survival. Conclusions: this is a real-life observation of a cohort of 344 long-term survivors with MM. The median age of the entire cohort was 59 years (range 27\u201383). The median years from diagnosis was 13.4 (range 11.3\u201316.3). Our analysis identified age more than 60 years, hypoalbuminemia at diagnosis, and a number of anti-myeloma therapies equal or more than 3 as significant independent prognostic factors for reduced OS. These finding underline the importance of designing prospective studies to identify clinical, biological, and molecular characteristics that could be used to better stratify newly diagnosed multiple myeloma pts in order to incorporate reproducible biomarkers and to identify tailored optimal target therapies.<\/jats:p>","DOI":"10.3390\/cancers17030354","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T07:55:32Z","timestamp":1737532532000},"page":"354","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Survival with Multiple Myeloma: An Italian Experience"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4187-8912","authenticated-orcid":false,"given":"Francesca","family":"Fazio","sequence":"first","affiliation":[{"name":"Hematology Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto I, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gherardini","sequence":"additional","affiliation":[{"name":"Hematology Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto I, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[{"name":"Section of Hematology, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, 00136 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Za","sequence":"additional","affiliation":[{"name":"Section of Hematology, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, 00136 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Landro","sequence":"additional","affiliation":[{"name":"Section of Hematology, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, 00136 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4398-7860","authenticated-orcid":false,"given":"Sonia","family":"Mor\u00e8","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Torrette, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Maria","family":"Manieri","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Torrette, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-9343","authenticated-orcid":false,"given":"Carmine","family":"Liberatore","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Oncology and Hematology, Pescara Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriela","family":"Chavez","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia, Ospedale Belcolle, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velia","family":"Bongarzoni","sequence":"additional","affiliation":[{"name":"Department of Hematology, San Giovanni-Addolorata Hospital, 00184 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Gumenyuk","sequence":"additional","affiliation":[{"name":"Hematology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Garzia","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hematology San Camillo Forlanini Hospital, 00152 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriana","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Haematology Service, Mazzoni Hospital, 63100 Ascoli Piceno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rago","sequence":"additional","affiliation":[{"name":"UOSD Ematologia ASL Roma1, 00193 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1487-5812","authenticated-orcid":false,"given":"Mario","family":"Biglietto","sequence":"additional","affiliation":[{"name":"Department of Hematology, S.M. Goretti Hospital, Polo Universitario Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Franceschini","sequence":"additional","affiliation":[{"name":"Hematology, Lymphoproliferative Disease Unit, Tor Vergata University Hospital, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Tomarchio","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Stem Cell Transplantation, University Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Padua","sequence":"additional","affiliation":[{"name":"UOC di Ematologia, Trapianto di Cellule Staminali e Terapia Genica, 95123 Frosinone, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8648-885X","authenticated-orcid":false,"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[{"name":"Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center, 00182 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-2467","authenticated-orcid":false,"given":"Andrea","family":"Mengarelli","sequence":"additional","affiliation":[{"name":"Hematology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fiorini","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia, Ospedale Belcolle, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fioritoni","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Oncology and Hematology, Pescara Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-7347","authenticated-orcid":false,"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Torrette, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5827","authenticated-orcid":false,"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Section of Hematology, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, 00136 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Hematology Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto I, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0688-4882","authenticated-orcid":false,"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[{"name":"Hematology Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto I, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000\u20132014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bjh.18658","article-title":"Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre","volume":"201","author":"Corvatta","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41375-021-01250-0","article-title":"Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods","volume":"35","author":"Corre","year":"2021","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): A multicenter, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mor\u00e8, S., Corvatta, L., Manieri, V.M., Saraceni, F., Scortechini, I., Mancini, G., Fiorentini, A., Olivieri, A., and Offidani, M. (2022). Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?. Cells, 11.","DOI":"10.3390\/cells11040606"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1002\/cncr.32357","article-title":"Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis","volume":"125","author":"Hsieh","year":"2019","journal-title":"Cancer"},{"key":"ref_9","first-page":"29","article-title":"Multiple myeloma: Review of 869 cases","volume":"50","author":"Kyle","year":"1975","journal-title":"Mayo Clin. Proc."},{"key":"ref_10","unstructured":"SEER (2021, September 10). Myeloma Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"ref_11","unstructured":"Cancer Research UK (2021, September 10). Myeloma Survival Statistics, Available online: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma#:~:text=Myeloma%20ten%2Dyear%20survival%20in,99%20(2013%2D2017)."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1080\/10428194.2021.2012665","article-title":"Long term survival in multiple myeloma: A single institution experience in underprivileged circumstances","volume":"63","author":"Gertz","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Usmani, S.Z., Hoering, A., Cavo, M., Miguel, J.S., Goldschimdt, H., Hajek, R., Turesson, I., Lahuerta, J.J., Attal, M., and Barlogie, B. (2018). Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma\u2014An IMWG Research Project. Blood Cancer J., 8.","DOI":"10.1038\/s41408-018-0155-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cam4.1283","article-title":"Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: Impact of clinical risk factors and sustained response","volume":"7","author":"Lehners","year":"2018","journal-title":"Cancer Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ccr3.76","article-title":"Long-term survival in multiple myeloma","volume":"2","author":"Costa","year":"2014","journal-title":"Clin. Case Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","author":"Blade","year":"2011","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3324\/haematol.13782","article-title":"Expected long-term survival of patients diagnosed with multiple myeloma in 2006\u20132010","volume":"94","author":"Brenner","year":"2009","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Raghavendra, M., Al-Hamadani, M., and Go, R.S. (2013). Long-Term (10 Years or More) Survivors Of Multiple Myeloma: A Population-Based Analysis Of The US National Cancer Data Base. Blood, 122.","DOI":"10.1182\/blood.V122.21.760.760"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10238-008-0169-8","article-title":"Long-term survival in multiple myeloma: A single-center experience","volume":"8","author":"Merchionne","year":"2008","journal-title":"Clin. Exp. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","article-title":"Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: An analysis of 10 549 patients from the International Myeloma Working Group","volume":"111","author":"Ludwig","year":"2008","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1600-0609.2006.00807.x","article-title":"Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System","volume":"78","author":"Sagaster","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/sj.leu.2403857","article-title":"Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma","volume":"19","author":"Ross","year":"2005","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s11912-024-01545-2","article-title":"Personalized Treatment of Multiple Myeloma in Frail Patients","volume":"26","author":"Lipof","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.blre.2010.10.003","article-title":"Management of older patients with multiple myeloma","volume":"25","author":"Gay","year":"2011","journal-title":"Blood Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"Liu","year":"2007","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11912-024-01537-2","article-title":"Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions","volume":"26","author":"Meseha","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_34","first-page":"2049","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-20-4366","article-title":"Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma","volume":"27","author":"Ziccheddu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic Classification and Individualized Prognosis in Multiple Myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_38","first-page":"2420","article-title":"Functional cure and long-term survival in multiple myeloma: How to challenge the previously impossible","volume":"109","author":"Engelhardt","year":"2024","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.clml.2019.03.017","article-title":"Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma","volume":"19","author":"Anwer","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/354\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:33:47Z","timestamp":1759919627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030354"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030354","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]}}}